Paper Details

  1. Home
  2. Paper Details

Molnupiravir provides little benefit in vaccinated adults with COVID-19.

Author:

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study reports the results of the PANORAMIC trial, which evaluated the effectiveness of molnupiravir plus usual care versus usual care alone for early treatment of COVID-19 in adults at increased risk of adverse outcomes. The trial found that molnupiravir resulted in a statistically significant reduction in hospital admission or death within 29 days, especially for those with high viral loads. However, the treatment effect decreased with increasing time from symptom onset, emphasizing the importance of early initiation.
Paper Details　
Original Abstract of the Article :
<b>Overview of:</b> Butler CC, Hobbs FDR, Gbinigie OA, <i>et al</i> Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. <i>Lancet</i> 2023;40...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/dtb.2023.000020

データ提供：米国国立医学図書館（NLM）

Molnupiravir: Limited Benefit for Vaccinated Adults with COVID-19

This study examines the effectiveness of molnupiravir, an antiviral medication, in treating vaccinated adults with COVID-19. Imagine a desert oasis offering relief from the harsh realities of the pandemic. The study, a randomized controlled trial, involved 10,388 vaccinated adults at increased risk for severe COVID-19. Patients were randomly assigned to receive either molnupiravir or usual care. The researchers found that molnupiravir provided little benefit in reducing hospitalizations or deaths among vaccinated adults with COVID-19.

Molnupiravir: Limited Effectiveness in Vaccinated Individuals

This study provides important insights into the use of molnupiravir in vaccinated individuals with COVID-19. The findings suggest that molnupiravir may not offer significant benefits in this population.

Navigating the Pandemic: The Importance of Vaccination

The COVID-19 pandemic continues to pose a significant challenge. This study reinforces the importance of vaccination as a primary strategy for protecting individuals from severe illness.

Dr. Camel's Conclusion

In the vast desert of the COVID-19 pandemic, we are constantly seeking new oases of hope. This study, while somewhat disappointing in terms of molnupiravir's effectiveness, underscores the crucial role of vaccination in mitigating the impact of this disease. As we continue to navigate this challenging landscape, we must remain vigilant in our efforts to protect ourselves and our communities.

Date :
  1. Date Completed 2023-06-02
  2. Date Revised 2023-06-02
Further Info :

Pubmed ID

37068918

DOI: Digital Object Identifier

10.1136/dtb.2023.000020

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.